Gilead, Fore­site take an un­known pan­dem­ic an­tivi­ral pub­lic in $250M SPAC deal

The SPAC boom has pro­duced some sur­pris­ing deals but gen­er­al­ly speak­ing, peo­ple fol­low­ing the in­dus­try have at least heard of the com­pa­nies go­ing pub­lic. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER